/GPCR
GPCR Stock - Structure Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$64.94+3.99%
+$2.49 (+3.99%) • Dec 19
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+38.6%upside
Target: $90.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GPCR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$64.29 – $65.59
TARGET (TP)$90.00
STOP LOSS$59.74
RISK/REWARD1:4.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.75
52W High$94.90
52W Low$13.22
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-20,034 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-158,228,000 | $-102,775,000 | $-52,561,000 | $-37,696,000 | $-15,933,378 |
| Net Income | $-122,526,000 | $-89,620,000 | $-51,321,000 | $-40,008,000 | $-15,903,326 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.34 | $-2.43 | $-1.44 | $-1.20 | $-0.45 |
Company Overview
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
10 Bullish0 Neutral/Bearish
Price Targets
$60
Average Target
↓ 7.1% Downside
Now
$33
Low
$60
Average
$118
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 2nd 2025 | Citigroup | Initiation | Buy | $60 |
| February 28th 2025 | William Blair | Initiation | Outperform | - |
| January 8th 2025 | Stifel | Initiation | Buy | $50 |
| December 4th 2024 | H.C. Wainwright | Initiation | Buy | $80 |
| September 23rd 2024 | Morgan Stanley | Initiation | Overweight | $118 |
| May 21st 2024 | JP Morgan | Initiation | Overweight | $65 |
| April 9th 2024 | Cantor Fitzgerald | Initiation | Overweight | $65 |
| October 19th 2023 | JMP Securities | Initiation | Mkt Outperform | $90 |
| July 27th 2023 | Piper Sandler | Initiation | Overweight | $58 |
| May 25th 2023 | Jefferies | Resumed | Buy | $41← $34 |
| February 28th 2023 | SVB Securities | Initiation | Outperform | $33 |
| February 28th 2023 | Guggenheim | Initiation | Buy | $50 |
| February 28th 2023 | Jefferies | Initiation | Buy | $34 |
| February 28th 2023 | BMO Capital Markets | Initiation | Outperform | $40 |
Earnings History & Surprises
GPCRBeat Rate
42%
Last 12 quarters
Avg Surprise
-18.5%
EPS vs Estimate
Beats / Misses
5/7
Last 12 quarters
Latest EPS
$-0.37
Q4 2025
EPS Surprise History
Q1 24
+19.0%
$-0.17vs$-0.21
Q2 24
+9.5%
$-0.19vs$-0.21
Q3 24
+21.7%
$-0.18vs$-0.23
Q4 24
-5.3%
$-0.20vs$-0.19
Q1 25
+4.3%
$-0.22vs$-0.23
Q2 25
-12.5%
$-0.27vs$-0.24
Q3 25
-28.6%
$-0.36vs$-0.28
Q4 25
-2.8%
$-0.37vs$-0.36
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.35 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.36 | $-0.37 | -2.8% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.28 | $-0.36 | -28.6% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.24 | $-0.27 | -12.5% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.23 | $-0.22 | +4.3% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.19 | $-0.20 | -5.3% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.23 | $-0.18 | +21.7% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.21 | $-0.19 | +9.5% | ✓ BEAT |
Q1 2024 | Mar 8, 2024 | $-0.21 | $-0.17 | +19.0% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.29 | $-0.62 | -113.8% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.28 | $-0.60 | -114.3% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.41 | $-0.25 | +39.0% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.82 | $-1.14 | -39.0% | ✗ MISS |
Q3 2022 | Sep 30, 2022 | — | $-0.12 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.13 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.12 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Latest News
Structure Therapeutics shares are trading higher after HC Wainwright & Co. raised the price target from $60 to $90.
📈 PositiveBenzinga•Dec 19, 2025, 06:07 PM
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Raises Price Target to $90
📈 PositiveBenzinga•Dec 19, 2025, 03:22 PM
Structure Therapeutics Initiates First-In-Human Phase 1 Clinical Study Of ACCG-2671, Lead Oral Small Molecule Amylin Receptor Agonist For Obesity Treatment
📈 PositiveBenzinga•Dec 17, 2025, 01:38 PM
Morgan Stanley Maintains Overweight on Structure Therapeutics, Raises Price Target to $125
📈 PositiveBenzinga•Dec 12, 2025, 05:13 PM
Citizens Maintains Market Outperform on Structure Therapeutics, Raises Price Target to $120
📈 PositiveBenzinga•Dec 12, 2025, 12:55 PM
Jefferies Maintains Buy on Structure Therapeutics, Raises Price Target to $125
📈 PositiveBenzinga•Dec 11, 2025, 07:27 PM•Also:
Reported Earlier, Structure Therapeutics Prices Upsized $650M Underwritten Offering Of ADSs And Pre-Funded Warrants At $65.00, Supporting Obesity-Focused Oral Therapeutics
📈 PositiveBenzinga•Dec 10, 2025, 08:13 AM
Citigroup Maintains Buy on Structure Therapeutics, Raises Price Target to $100
📈 PositiveBenzinga•Dec 9, 2025, 07:40 PM•Also:
Stifel Maintains Buy on Structure Therapeutics, Raises Price Target to $90
📈 PositiveBenzinga•Dec 9, 2025, 01:56 PM•Also:
Clear Street Maintains Buy on Structure Therapeutics, Raises Price Target to $99
📈 PositiveBenzinga•Dec 9, 2025, 12:22 PM
Structure Therapeutics Announces Proposed $500M Public Offering Of ADS And Pre-Funded Warrants
➖ NeutralBenzinga•Dec 8, 2025, 09:02 PM
Structure Therapeutics surges on phase 2 data for GLP-1 pill aleniglipron
📈 PositiveSeeking Alpha•Dec 8, 2025, 03:23 PM
Structure Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 132.09%
➖ NeutralBenzinga•Dec 8, 2025, 03:19 PM
Structure Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 121.99%
📈 PositiveBenzinga•Dec 8, 2025, 03:08 PM
Structure Therapeutics shares are trading higher after the company announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity.
📈 PositiveBenzinga•Dec 8, 2025, 01:08 PM
Structure Therapeutics Reports Topline Data From ACCESS Program For Aleniglipron
➖ NeutralBenzinga•Dec 8, 2025, 01:07 PM
Reported Sunday, Structure Therapeutics To Share ACCESS Program Topline Data For Aleniglipron Oral GLP-1 Receptor Agonist, Hosting Call Dec 8, 2025
➖ NeutralBenzinga•Dec 8, 2025, 08:07 AM
FDA Launches Green List To Protect Americans From Illegal Imported GLP-1 Drug Ingredients
➖ NeutralBenzinga•Sep 5, 2025, 03:40 PM•Also: , ,
Frequently Asked Questions about GPCR
What is GPCR's current stock price?
Structure Therapeutics Inc. (GPCR) is currently trading at $64.94 per share. The stock has moved +3.99% today.
What is the analyst price target for GPCR?
The average analyst price target for GPCR is $90.00, based on 1 analyst.
What sector is Structure Therapeutics Inc. in?
Structure Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GPCR's market cap?
Structure Therapeutics Inc. has a market capitalization of $3.74 billion, making it a mid-cap company.
Does GPCR pay dividends?
No, Structure Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
EWTX
Edgewise Therapeutics, Inc.
$25.55
Mkt Cap: $2.7B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
LQDA
Liquidia Corporation
$34.53
Mkt Cap: $3.0B
MESO
Mesoblast Limited
$19.48
Mkt Cap: $2.5B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
OCUL
Ocular Therapeutix, Inc.
$12.56
Mkt Cap: $2.2B
QURE
uniQure N.V.
$23.99
Mkt Cap: $1.3B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to GPCR for comparison